Evidence map›Paper›PMID 26449523›Full record

ArticleToxicology2015

The cytotoxicity of the α1-adrenoceptor antagonist prazosin is linked to an endocytotic mechanism equivalent to transport-P.

Robert Fuchs, Anika Stracke, Nadine Ebner, Christian Wolfgang Zeller, Anna Maria Raninger, Matthias Schittmayer, Tatjana Kueznik, Markus Absenger-Novak, Ruth Birner-Gruenberger

Open access · hybridAbstract read
In one paragraph

Article in Toxicology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Robert FuchsInstitute of Pathophysiology and Immunology, Centre of Molecular Medicine, Medical University of Graz, Heinrichstrasse 31A, 8010 Graz, Austria. Electronic address: robert.fuchs@medunigraz.at.
Anika StrackeInstitute of Pathophysiology and Immunology, Centre of Molecular Medicine, Medical University of Graz, Heinrichstrasse 31A, 8010 Graz, Austria. Electronic address: anika.stracke@medunigraz.at.
Nadine EbnerInstitute of Pathophysiology and Immunology, Centre of Molecular Medicine, Medical University of Graz, Heinrichstrasse 31A, 8010 Graz, Austria. Electronic address: nadine.ebner3@gmail.com.
Christian Wolfgang ZellerInstitute of Pathophysiology and Immunology, Centre of Molecular Medicine, Medical University of Graz, Heinrichstrasse 31A, 8010 Graz, Austria. Electronic address: chri_zeller@web.de.
Anna Maria RaningerInstitute of Pathophysiology and Immunology, Centre of Molecular Medicine, Medical University of Graz, Heinrichstrasse 31A, 8010 Graz, Austria. Electronic address: annaraninger@hotmail.com.
Matthias SchittmayerResearch Unit Functional Proteomics and Metabolic Pathways, Institute of Pathology, Medical University of Graz and Omics Center Graz, BioTechMed-Graz, Stiftingtalstrasse 24, 8010 Graz, Austria. Electronic address: matthias.schittmayer@medunigraz.at.
Tatjana KueznikCentre for Medical Research, Medical University of Graz, Stiftingtalstrasse 24, 8010 Graz, Austria. Electronic address: tatjana.kueznik@medunigraz.at.
Markus Absenger-NovakCentre for Medical Research, Medical University of Graz, Stiftingtalstrasse 24, 8010 Graz, Austria. Electronic address: markus.absenger@medunigraz.at.
Ruth Birner-GruenbergerResearch Unit Functional Proteomics and Metabolic Pathways, Institute of Pathology, Medical University of Graz and Omics Center Graz, BioTechMed-Graz, Stiftingtalstrasse 24, 8010 Graz, Austria. Electronic address: ruth.birner-gruenberger@medunigraz.at.
Medical University of Graz · ATBioTechMed-Graz · ATUniversity of Graz · AT

Funding

Austrian Science Fund FWF P 24006
6 · The paper itself

Abstract

Since the α1-adrenergic antagonist prazosin (PRZ) was introduced into medicine as a treatment for hypertension and benign prostate hyperplasia, several studies have shown that PRZ induces apoptosis in various cell types and interferes with endocytotic trafficking. Because PRZ is also able to induce apoptosis in malignant cells, its cytotoxicity is a focus of interest in cancer research. Besides inducing apoptosis, PRZ was shown to serve as a substrate for an amine uptake mechanism originally discovered in neurones called transport-P. In line with our hypothesis that transport-P is an endocytotic mechanism also present in non-neuronal tissue and linked to the cytotoxicity of PRZ, we tested the uptake of QAPB, a fluorescent derivative of PRZ, in cancer cell lines in the presence of inhibitors of transport-P and endocytosis. Early endosomes and lysosomes were visualised by expression of RAB5-RFP and LAMP1-RFP, respectively; growth and viability of cells in the presence of PRZ and uptake inhibitors were also tested. Cancer cells showed co-localisation of QAPB with RAB5 and LAMP1 positive vesicles as well as tubulation of lysosomes. The uptake of QAPB was sensitive to transport-P inhibitors bafilomycin A1 (inhibits v-ATPase) and the antidepressant desipramine. Endocytosis inhibitors pitstop(®) 2 (general inhibitor of endocytosis), dynasore (dynamin inhibitor) and methyl-β-cyclodextrin (cholesterol chelator) inhibited the uptake of QAPB. Bafilomycin A1 and methyl-β-cyclodextrin but not desipramine were able to preserve growth and viability of cells in the presence of PRZ. In summary, we confirmed the hypothesis that the cellular uptake of QAPB/PRZ represents an endocytotic mechanism equivalent to transport-P. Endocytosis of QAPB/PRZ depends on a proton gradient, dynamin and cholesterol, and results in reorganisation of the LAMP1 positive endolysosomal system. Finally, the link seen between the cellular uptake of PRZ and cell death implies a still unknown pro-apoptotic membrane protein with affinity towards PRZ.

Indexed as

Adrenergic alpha-1 Receptor AntagonistsAntineoplastic AgentsApoptosisBoron CompoundsCell ProliferationCell SurvivalCholesterolDynaminsEndocytosisEndosomesFluorescent DyesHumansHydrogen-Ion ConcentrationK562 CellsLysosomal-Associated Membrane Protein 1Lysosomal Membrane ProteinsAdrenergic alpha-1 Receptor AntagonistsAntineoplastic AgentsBODIPY-FL prazosinBoron CompoundsCholesterolDynaminsFluorescent DyesLAMP1 protein, humanLysosomal-Associated Membrane Protein 1Lysosomal Membrane ProteinsPrazosinRAB5C protein, humanrab5 GTP-Binding ProteinsApoptosisEndocytosisLysosomesPrazosinTransport-P

Identifiers

PMID26449523
PMCPMC4671317
OpenAlexW1919351463

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.